Phaseline

Targets › IL6R

IL6R (Interleukin-6 receptor subunit alpha): drug programs, companies and trials

11 programs from 9 companies in 73 trials: 32 Phase 2, 26 Phase 3, 11 Phase 1, 4 Phase 4; Immunology, Neurology, Oncology; next expected readout Nov 2026.

Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal. (UniProt, P08887)

Open in Phaseline: the race on IL6R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
RocheSatralizumab
IL6Ralpha/GP130 antagonist
IL6R, IL6STPhase 3NMDAR Autoimmune Encephalitis; Neuromyelitis Optica Spectrum Disorder; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD); Duchenne Muscular Dystrophy …Nov 2026
Johnson & Johnson (Janssen)Icotrokinra (JNJ-77242113)
IL-6 receptor antagonist
IL6RPhase 3Arthritis, Psoriatic; Plaque Psoriasis; Colitis, Ulcerative; Crohn DiseaseFeb 2027
Kodiak SciencesKSI-101
IL-6 receptor antagonist (IL-6R-Fc fusion protein)
IL6RPhase 3Macular Edema Secondary to InflammationFeb 2027
Beijing VDJBioVDJ001
IL-6 receptor antagonist monoclonal antibody
IL6RPhase 3Anti IL-6RJun 2027
BiocadLevilimab
Interleukin-6 receptor alpha subunit inhibitor
IL6RPhase 3Rheumatoid ArthritisDec 2027
SanofiSarilumab (SAR153191)
Interleukin-6 receptor alpha subunit antagonist
IL6RPhase 3Polymyalgia Rheumatica; Juvenile Idiopathic Arthritis; Rheumatoid Arthritis; Melanoma …Mar 2028
R-PharmRPH-104
IL-6 receptor antagonist
IL6RPhase 3Idiopathic Recurrent Pericarditis; Familial Mediterranean FeverDec 2028
Beijing VDJBioRecombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection
anti-IL-6 receptor monoclonal antibody
IL6RPhase 2Idiopathic Multicentric Castleman's Disease–
RocheTocilizumab
Interleukin-6 receptor alpha subunit inhibitor
IL6RPhase 1Advanced Liver Cancers; Takayasu Arteritis; Primary Cutaneous Amyloidosis; Giant Cell Arteritis …Jul 2027
University of Floridatocilizumab-aazg (TYENNE)
IL-6 receptor antagonist (anti-IL-6R monoclonal antibody)
IL6RPhase 1Aneurysmal Subarachnoid HemorrhageJul 2028
Innovent Biologics (Suzhou)IBI3011
Anti-IL-RAP humanised monoclonal antibody
IL6RPhase 1Acute Gout Flare–

Conditions

Plaque Psoriasis (5) Rheumatoid Arthritis (2) Arthritis, Psoriatic (2) Melanoma (2) Takayasu Arteritis (2) Giant Cell Arteritis (2) Sickle Cell Disease (2) Familial Mediterranean Fever (2) Macular Edema Secondary to Inflammation (2) Idiopathic Multicentric Castleman's Disease (1) Colitis, Ulcerative (1) Crohn Disease (1)

Modalities

antibody (6), protein or peptide (2), small molecule (2), mixed (1)

Companies

Beijing VDJBio (2) Roche (2) Biocad (1) Johnson & Johnson (Janssen) (1) Innovent Biologics (Suzhou) (1) Sanofi (1) R-Pharm (1) Kodiak Sciences (1) University of Florida (1)

Related targets

IL6ST (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.